These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 21590495

  • 1. Prognostic value of intercellular adhesion molecule (ICAM)-1 expression in breast cancer.
    Schröder C, Witzel I, Müller V, Krenkel S, Wirtz RM, Jänicke F, Schumacher U, Milde-Langosch K.
    J Cancer Res Clin Oncol; 2011 Aug; 137(8):1193-201. PubMed ID: 21590495
    [Abstract] [Full Text] [Related]

  • 2. Prognostic significance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) in patients with primary invasive ductal breast carcinoma - a 7.5-year follow-up study.
    Jelisavac-Cosic S, Sirotkovic-Skerlev M, Kulic A, Jakic-Razumovic J, Kovac Z, Vrbanec D.
    Tumori; 2011 Aug; 97(4):532-9. PubMed ID: 21989445
    [Abstract] [Full Text] [Related]

  • 3. Correlation of Serum Levels of Urokinase Activation Plasminogen (uPA) and Its Inhibitor (PAI-1) with Hormonal and HER-2 Status in the Early Invasive Breast Cancer.
    Pusina S.
    Med Arch; 2018 Nov; 72(5):335-340. PubMed ID: 30524164
    [Abstract] [Full Text] [Related]

  • 4. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.
    Foekens JA, Look MP, Peters HA, van Putten WL, Portengen H, Klijn JG.
    J Natl Cancer Inst; 1995 May 17; 87(10):751-6. PubMed ID: 7563153
    [Abstract] [Full Text] [Related]

  • 5. Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up.
    Buta M, Džodić R, Đurišić I, Marković I, Vujasinović T, Markićević M, Nikolić-Vukosavljević D.
    Tumour Biol; 2015 Sep 17; 36(10):8193-200. PubMed ID: 25994573
    [Abstract] [Full Text] [Related]

  • 6. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.
    Foekens JA, Schmitt M, van Putten WL, Peters HA, Kramer MD, Jänicke F, Klijn JG.
    J Clin Oncol; 1994 Aug 17; 12(8):1648-58. PubMed ID: 8040677
    [Abstract] [Full Text] [Related]

  • 7. Markers of progression and invasion in short term follow up of untreated breast cancer patients.
    Rabi ZA, Todorović-Raković N, Vujasinović T, Milovanović J, Nikolić-Vukosavljević D.
    Cancer Biomark; 2015 Aug 17; 15(6):745-54. PubMed ID: 26406416
    [Abstract] [Full Text] [Related]

  • 8. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.
    Zemzoum I, Kates RE, Ross JS, Dettmar P, Dutta M, Henrichs C, Yurdseven S, Höfler H, Kiechle M, Schmitt M, Harbeck N.
    J Clin Oncol; 2003 Mar 15; 21(6):1022-8. PubMed ID: 12637466
    [Abstract] [Full Text] [Related]

  • 9. Comparison of microarray-based RNA expression with ELISA-based protein determination of HER2, uPA and PAI-1 in tumour tissue of patients with breast cancer and relation to outcome.
    Witzel ID, Milde-Langosch K, Wirtz RM, Roth C, Ihnen M, Mahner S, Zu Eulenburg C, Jänicke F, Müller V.
    J Cancer Res Clin Oncol; 2010 Nov 15; 136(11):1709-18. PubMed ID: 20204407
    [Abstract] [Full Text] [Related]

  • 10. Detection of Survivin-expressing circulating cancer cells in the peripheral blood of breast cancer patients by a RT-PCR ELISA.
    Yie SM, Luo B, Ye NY, Xie K, Ye SR.
    Clin Exp Metastasis; 2006 Nov 15; 23(5-6):279-89. PubMed ID: 17086357
    [Abstract] [Full Text] [Related]

  • 11. Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse.
    Harbeck N, Thomssen C, Berger U, Ulm K, Kates RE, Höfler H, Jänicke F, Graeff H, Schmitt M.
    Breast Cancer Res Treat; 1999 Mar 15; 54(2):147-57. PubMed ID: 10424405
    [Abstract] [Full Text] [Related]

  • 12. VEGF expression is associated with negative estrogen receptor status in patients with breast cancer.
    Fuckar D, Dekanić A, Stifter S, Mustać E, Krstulja M, Dobrila F, Jonjić N.
    Int J Surg Pathol; 2006 Jan 15; 14(1):49-55. PubMed ID: 16501835
    [Abstract] [Full Text] [Related]

  • 13. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
    Konecny G, Untch M, Arboleda J, Wilson C, Kahlert S, Boettcher B, Felber M, Beryt M, Lude S, Hepp H, Slamon D, Pegram M.
    Clin Cancer Res; 2001 Aug 15; 7(8):2448-57. PubMed ID: 11489825
    [Abstract] [Full Text] [Related]

  • 14. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R, Schaaf A.
    Int J Oncol; 2009 Jan 15; 34(1):15-23. PubMed ID: 19082473
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Basal-like immunophenotype markers and prognosis in early breast cancer.
    Cassol L, Silveira Graudenz M, Zelmanowicz A, Cancela A, Werutsky G, Rovere RK, Garicochea B.
    Tumori; 2010 Jan 15; 96(6):966-70. PubMed ID: 21388060
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The associations between mast cell infiltration, clinical features and molecular types of invasive breast cancer.
    Sang J, Yi D, Tang X, Zhang Y, Huang T.
    Oncotarget; 2016 Dec 06; 7(49):81661-81669. PubMed ID: 27835573
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.